Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996

Background: In the era before highly active antiretroviral therapy (HAART), socioeconomic status was associated with survival from HIV disease. We have explored socioeconomic status, access to triple therapy (HAART), and mortality in the context of a universal healthcare system. Methods: We evaluated 1408 individuals who initiated double or triple therapy between 1 August 1996 and 31 December 1999, and were followed until 31 March 2000. Cumulative HIV-related mortality rates were estimated using Kaplan–Meier methods and Cox proportional hazards regression. Results: In the overall Cox model, we found that adherence [risk ratio (RR) 0.83; per 10% increase], CD4 cell count (RR 1.53; per 100 cell decrease), and lower socioeconomic status (RR 2.19; high versus low), were associated with HIV-related mortality. However, socioeconomic status was not significant among patients prescribed triple therapy in a stratified analysis, or in a sub-analysis restricted to patients prescribed HAART in the initial regimen. When we investigated if inequitable access to HAART by socio-economic status could explain the discrepancy, we found that persons in the lower socio-economic strata were less likely to be prescribed triple therapy even after adjustment for clinical characteristics. Conclusion: In a universal healthcare system, socioeconomic status was strongly associated with HIV-related mortality. When we investigated possible explanations for this association, we found that individuals of lower socioeconomic status were less likely to receive triple therapy after adjustment for clinical characteristics. Our findings highlight the need for the monitoring of therapeutic guidelines to ensure equitable access, as treatment strategies are updated.

[1]  R. Hogg,et al.  Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[2]  T. Louis,et al.  Survival and disease progression according to gender of patients with HIV infection. The Terry Beirn Community Programs for Clinical Research on AIDS. , 1994, JAMA.

[3]  J. Montaner,et al.  A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.

[4]  R. Chaisson,et al.  Racial differences in the use of drug therapy for HIV disease in an urban community. , 1994, The New England journal of medicine.

[5]  R. Donovan,et al.  Misclassification of social disadvantage based on geographical areas: comparison of postcode and collector's district analyses. , 1995, International journal of epidemiology.

[6]  B. Yip,et al.  Barriers to use of free antiretroviral therapy in injection drug users. , 1998, JAMA.

[7]  R. Hogg,et al.  Higher socioeconomic status is associated with slower progression of HIV infection independent of access to health care. , 1994, Journal of clinical epidemiology.

[8]  R. Hogg,et al.  Adherence to triple therapy and viral load response. , 2000, Journal of acquired immune deficiency syndromes.

[9]  J. Montaner,et al.  A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.

[10]  Julio S. G. Montaner,et al.  Lower socioeconomic status and shorter survival following HIV infection , 1994, The Lancet.

[11]  R. Chaisson,et al.  Race, sex, drug use, and progression of human immunodeficiency virus disease. , 1995, The New England journal of medicine.

[12]  S. Deeks.  Determinants of virological response to antiretroviral therapy: implications for long-term strategies. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[14]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[15]  J A Hanley,et al.  Agreement in measuring socio-economic status: area-based versus individual measures. , 2000, Chronic diseases in Canada.

[16]  M. Schechter,et al.  Social inequalities in male mortality amenable to medical intervention in British Columbia. , 1999, Social science & medicine.

[17]  F. Forastiere,et al.  Socioeconomic status and survival of persons with AIDS before and after the introduction of highly active antiretroviral therapy. Lazio AIDS Surveillance Collaborative Group. , 2000, Epidemiology.

[18]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[19]  R. Weber,et al.  Effects of Early Antiretroviral Treatment on HIV‐1 RNA in Blood and Lymphoid Tissue: A Randomized Trial of Double Versus Triple Therapy , 2000, Journal of acquired immune deficiency syndromes.

[20]  R. Chaisson,et al.  Zidovudine and the natural history of the acquired immunodeficiency syndrome. , 1991, The New England journal of medicine.

[21]  M. Jacobson,et al.  Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. , 1998, AIDS.

[22]  J A Fleishman,et al.  Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. , 1999, JAMA.

[23]  Evan Wood,et al.  Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa , 2000, The Lancet.

[24]  T Creagh-Kirk,et al.  Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease. Zidovudine Epidemiology Study Group. , 1991, JAMA.

[25]  F. Forastiere,et al.  Socioeconomic Status and Survival of Persons with AIDS before and after the Introduction of Highly Active Antiretroviral Therapy , 2000 .

[26]  R. Hogg,et al.  Do dual nucleoside regimens have a role in an era of plasma viral load-driven antiretroviral therapy? , 1998, The Journal of infectious diseases.

[27]  B. Yip,et al.  Antiviral effect of double and triple drug combinations amongst HIV‐infected adults: lessons from the implementation of viral load‐driven antiretroviral therapy , 1998, AIDS.

[28]  J. M. Mitchell,et al.  Differential access in the receipt of antiretroviral drugs for the treatment of AIDS and its implications for survival. , 2000, Archives of internal medicine.

[29]  R. Hogg,et al.  Socio-Demographic Profile and Hiv and Hepatitis C Prevalence Among Persons Who Died of a Drug Overdose , 2001 .

[30]  Douglas D. Richman,et al.  Racial and Ethnic Differences in Outcome in Zidovudine-Treated Patients With Advanced HIV Disease , 1991 .

[31]  R. Hogg,et al.  Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. , 2001, AIDS.

[32]  Julio S. G. Montaner,et al.  Antiretroviral medication use among injection drug users: two potential futures , 2000, AIDS.

[33]  F. Hecht,et al.  Provider Assessment of Adherence to HIV Antiretroviral Therapy , 2001, Journal of acquired immune deficiency syndromes.

[34]  F. Hecht,et al.  Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population , 2000, AIDS.

[35]  M. Schechter,et al.  Impact of HIV Infection on Mortality in a Cohort of Injection Drug Users , 2001, Journal of acquired immune deficiency syndromes.

[36]  M A Fischl,et al.  Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel , 2000 .

[37]  R. Hogg,et al.  Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. , 1998, JAMA.

[38]  P. Harrigan,et al.  Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. , 1998, The Journal of infectious diseases.

[39]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[40]  M. J. van der Werf,et al.  Highly active antiretroviral therapy among drug users in Amsterdam: self-perceived reasons for not receiving therapy. , 1999, AIDS.

[41]  B. Truman,et al.  Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City. , 1987, The New England journal of medicine.

[42]  M. Lederman,et al.  Should physicians withhold highly active antiretroviral therapies from HIV-AIDS patients who are thought to be poorly adherent to treatment? , 2001, AIDS.

[43]  M. Katz,et al.  Impact of socioeconomic status on survival with AIDS. , 1998, American journal of epidemiology.

[44]  J L Kelsey,et al.  The measurement of social class in epidemiology. , 1988, Epidemiologic reviews.